Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Maoni, Guo"'
Publikováno v:
Oncogenesis, Vol 11, Iss 1, Pp 1-8 (2022)
Abstract BRCA1 mutation is the genetic predisposition in causing genome instability towards cancer. BRCA1 mutation is predominantly germline inherited at the fertilization. However, when the inherited mutation initiates genome instability in the muta
Externí odkaz:
https://doaj.org/article/5485af4bf19b4a3abd61f0c6e0cafd2b
Autor:
Maoni Guo, San Ming Wang
Publikováno v:
Cells, Vol 11, Iss 23, p 3877 (2022)
BRCAness refers to the damaged homologous recombination (HR) function due to the defects in HR-involved non-BRCA1/2 genes. BRCAness is the important marker for the use of synthetic lethal-based PARP inhibitor therapy in breast and ovarian cancer trea
Externí odkaz:
https://doaj.org/article/f2dfe7695468472e864afacf9baaa36b
Autor:
Maoni Guo, San Ming Wang
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
BackgroundTriple-negative breast cancer (TNBC) is an aggressive disease. Recent studies have identified genome instability-derived genes for patient outcomes. However, most of the studies mainly focused on only one or a few genome instability-related
Externí odkaz:
https://doaj.org/article/9d8fb3b19a99469f882f91c8e2658294
Autor:
Jizhou Zhang, Yue Gao, Peng Wang, Hui Zhi, Yan Zhang, Maoni Guo, Ming Yue, Xin Li, Dianshuang Zhou, Yanxia Wang, Weitao Shen, Junwei Wang, Jian Huang, Shangwei Ning
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
Identification and characterization of lncRNAs in cancer with a view to their application in improving diagnosis and therapy remains a major challenge that requires new and innovative approaches. We have developed an integrative framework termed “C
Externí odkaz:
https://doaj.org/article/7a040e21ccc64385b7a0fc63f81301a2
Autor:
Yan Zhang, Xin Li, Dianshuang Zhou, Hui Zhi, Peng Wang, Yue Gao, Maoni Guo, Ming Yue, Yanxia Wang, Weitao Shen, Shangwei Ning, Yixue Li, Xia Li
Publikováno v:
Molecular Oncology, Vol 12, Iss 9, Pp 1429-1446 (2018)
Differences in individual drug responses are an obstacle to progression in cancer treatment, and predicting responses would help to plan treatment. The accumulation of cancer molecular profiling and drug response data provides opportunities and chall
Externí odkaz:
https://doaj.org/article/6c84f1539b144606acd8c324d4c40f3c
Autor:
Zixin Qin, Jiaheng Li, Benjamin Tam, Siddharth Sinha, Bojin Zhao, Shanmuga Priya Bhaskaran, Teng Huang, Xiaobing Wu, Jia Sheng Chian, Maoni Guo, Si Hoi Kou, Huijun Lei, Li Zhang, Xiaoyu Wang, Philip Naderev P. Lagniton, Fengxia Xiao, Xinyang Jiang, San Ming Wang
Publikováno v:
International Journal of Cancer. 152:1159-1173
Pathogenic variation in BRCA1 and BRCA2 (BRCA) causes high risk of breast and ovarian cancer, and BRCA variation data are important markers for BRCA-related clinical cancer applications. However, comprehensive BRCA variation data are lacking from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8236a9cd361f299ad06ea28e2d6b97a
https://doi.org/10.1002/ijc.34359
https://doi.org/10.1002/ijc.34359
Autor:
Maoni Guo, Zixin Qin, Jiasheng Chian, Suicheng Li, Jiangtao Luo, Shanmuga Priya Bhaskaran, Teng Huang, San Ming Wang, Bojin Zhao, Barani Kumar Rajendran
Publikováno v:
Journal of Medical Genetics. 58:752-759
BackgroundGermline mutation in BRCA1 and BRCA2 (BRCA) is genetic predisposition for breast and ovarian cancer. Identification of mutation carriers is a critical step to prevent and treat the cancer in the mutation carriers. Human BRCA variation has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de680c801aaa1699a419f5e19288715b
https://doi.org/10.1136/jmedgenet-2020-107299
https://doi.org/10.1136/jmedgenet-2020-107299
Autor:
San Ming Wang, Hui Dong, Maoni Guo, Luhan Jiang, Grace Meng, Lei Wang, Zixin Qin, Cheong Nang Kuok, Hio Kuan Leong, Li Zhang
Publikováno v:
Journal of Medical Genetics. 58:587-591
BackgroundPathogenic mutation in BRCA genes causes high cancer risk. Identifying the mutation carriers plays key roles in preventing BRCA mutation-related cancer. Population screening has demonstrated its power for comprehensive identification of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f6e6fbdf30c74aa73965e1e135e277f
https://doi.org/10.1136/jmedgenet-2020-107181
https://doi.org/10.1136/jmedgenet-2020-107181
Autor:
Ce Rong, Guoping Zhao, Maoni Guo, San Ming Wang, Ning Wang, Hui Dong, Xiaoqing Tian, Jing Zhang, Yue Qin, Khyati Chandratre
Publikováno v:
Journal of Medical Genetics. 58:565-569
BackgroundPathogenic variation inBRCA1andBRCA2(BRCA) is one of the most frequent genetic predispositions for hereditary breast cancer. The identification of the variant carriers plays an important role in prevention and treatment of cancer. Despite a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a9321c929cdbd724eeab00e21b28807
https://doi.org/10.1136/jmedgenet-2020-106970
https://doi.org/10.1136/jmedgenet-2020-106970
Publikováno v:
Oncogenesis. 11(1)
BRCA1 mutation is the genetic predisposition in causing genome instability towards cancer. BRCA1 mutation is predominantly germline inherited at the fertilization. However, when the inherited mutation initiates genome instability in the mutation carr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e6079a6321993fac96b1858fdc8f13
https://pubmed.ncbi.nlm.nih.gov/35869059
https://pubmed.ncbi.nlm.nih.gov/35869059